Scholars Central

Research articlePublished 25 Sep 2023

ARDiTox: Platform for the Prediction of T-Cell Receptors (TCRs) Potential Off-Target Binding

Authors: Victor Murcia Pienkowski, Tamara Boschert, Piotr Skoczylas, Anna Sanecka-Duin, Maciej Jasinski, Bartlomiej Krol-Jozaga, Giovanni Mazzocco, Slawomir Stachura, Lukas Bunse, Jan Kaczmarczyk, Edward W. Green, Agnieszka Blum

Journal of Proteomics & Bioinformatics

Volume 16 · Issue 3 · Pages 1–10

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Cellular immunotherapies, such as those utilizing T lymphocytes expressing native or engineered T-cell Receptors (TCRs), have already demonstrated therapeutic efficacy. However, some high-affinity TCRs have also proved to be fatal due to off-target immunotoxicity. This process occurs when the immune system acts against epitopes found on both tumor cells and healthy tissues. Moreover, some TCRs can be cross-reactive to epitopes with highly dissimilar sequences. To address this issue, we developed ARDitox, a novel in silico method based on computational immunology and Artificial Intelligence (AI), for predicting and analyzing potential off-target toxicities. We tested the performance of ARDitox in silico on 4 different epitopes found in the literature where TCRs were used to target cancer-related antigens as well as on a set of TCR targeting a viral epitope. Two of them have a specific clinical outcome in which immunotoxicity was reported (MAGEA3112-120 and MAGEA3168-176 epitopes), one was tested using an X-scan approach (AFP158-166 epitope), and the last one with no cross-reactive epitopes identified in clinical trials (NY-ESO-1157-165 epitope). Overall, ARDitox has identified immunotoxic epitopes in line with the data available in the literature. In addition, we investigated a very promising TCR, which is still in development, against a peptide coded by the NLGN4X gene. For this epitope, we detected a cross-reactive peptide that otherwise would be difficult to detect in vitro. In conclusion, in silico approach is a powerful tool that accurately identifies off-target epitopes and should be considered in preclinical studies, as it can effectively complement the development of safer anti-cancer therapies.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Proteomics & Bioinformatics
  • SubjectBiochemistry & Biotechnology
  • BylineArticles whose byline prints “Victor Murcia Pienkowski”
  • BylineArticles whose byline prints “Tamara Boschert”
  • BylineArticles whose byline prints “Piotr Skoczylas”
  • BylineArticles whose byline prints “Anna Sanecka-Duin”
  • BylineArticles whose byline prints “Maciej Jasinski”
  • BylineArticles whose byline prints “Bartlomiej Krol-Jozaga”
  • BylineArticles whose byline prints “Giovanni Mazzocco”
  • BylineArticles whose byline prints “Slawomir Stachura”